StreetAlpha
13F holdings · Q3 2026

Elmind Capital

New York, NY · files as Elmind Capital, LP
Know the moment Elmind Capital filesYou follow Elmind Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2052213

Elmind Capital reported 30 stocks worth $404M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CLDX (8.9%), LEGN (7.7%) and SNDX (7.5%). Compared with Q2 2026, the fund added to CLDX, LEGN and AMLX, trimmed SNDX, COGT and PCVX and sold out of INSM, PTGX and WVE.

Latest filing: what Elmind Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
0 new11 added5 trimmed5 sold outBought about $85.6M · sold about $36.6M
New 0

None

Added 11
See all 11 →
Trimmed 5
Sold out 5

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$404M+1.5% vs last quarter
Stocks held300 new · 5 sold out
Top 5 weight37.5%fairly concentrated
Turnover30%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
CLDX
Celldex Therapeutics Inc
$36M8.9%1.1M+120K (+12%)4 of 4
2
LEGN
Legend Biotech Corp
$31.2M7.7%1.6M+999K (+175%)2 of 4
3
SNDX
Syndax Pharmaceuticals Inc
$30.2M7.5%1.6M−250K (−13%)4 of 4
4
COGT
Cogent Biosciences Inc
$27.8M6.9%867K−304K (−26%)4 of 4
5
RLAY
Relay Therapeutics Inc
$26.4M6.5%1.5MNo change4 of 4
6
AMLX
Amylyx Pharmaceuticals Inc
$26M6.5%895K+783K (+699%)4 of 4
7
VRDN
Viridian Therapeutics Inc
$25.2M6.3%1.2M+240K (+24%)4 of 4
8
PCVX
Vaxcyte Inc
$21.2M5.3%372K−80K (−18%)4 of 4
9
URGN
Urogen Pharma Ltd
$20M4.9%491K+371K (+309%)4 of 4
10
TVTX
Travere Therapeutics Inc
$19M4.7%323K+30K (+10%)4 of 4
🔒 20 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
INSM
Insmed Inc
$6.9M65K
PTGX
Protagonist Therapeutics Inc
$4.7M38K
WVE
Wave Life Sciences Ltd
$1M178K
TYRA
Tyra Biosciences Inc
$639K20K
ENGN
Engene Therapeut
$363K210K

Reported value

last 4 quarters
$339MQ4 '25
$352MQ1 '26
$398MQ2 '26
$404MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Elmind Capital 13F FAQ

What does Elmind Capital own?

Elmind Capital reported 30 stocks worth $404M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CLDX (8.9%), LEGN (7.7%) and SNDX (7.5%). The table above lists every position in the filing (the top 10 without an account).

What did Elmind Capital buy and sell in Q3 2026?

Compared with Q2 2026: 0 new positions, 11 added to, 5 trimmed and 5 sold out. It sold all of INSM, PTGX and WVE.

When will Elmind Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Elmind Capital's portfolio worth?

The Q3 2026 filing reports $404M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.